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Abstract  
This pilot study assesses the impact of FREED [First Episode and Rapid Early Intervention for 
Eating Disorders (ED)], a novel transdiagnostic service for emerging adults with recent ED 
onset, on clinical outcomes. Data were collected from 56 patients and 19 carers for 12 months 
following enrolment. FREED patients showed significant improvements in ED and other 
symptoms across time. Carers also showed psychological improvements.  For FREED anorexia 
nervosa (AN) patients, body mass index (BMI) at initial clinical assessment was similar to that 
of comparable patients (Audit cohort) seen in our service before (16.4 vs 16.1 kg/m2). By start 
of treatment, because of their shorter wait, FREED-AN had gained weight whereas Audit 
patients’ had lost (16.7 vs 15.8 kg/m2). This difference continued throughout treatment and at 
12 months nearly 60% FREED-AN returned to a BMI 18.5 or greater. FREED shows promise 
as a service model for emerging adults with EDs.  
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INTRODUCTION  
Eating disorders (EDs) are common mental disorders, with the peak age of onset spanning 
adolescence and early adulthood (Micali, Hagberg, Petersen, & Treasure, 2013; Schmidt, 
Brown, McClelland, Glennon, & Mountford, 2016). In other psychiatric disorders, intervening 
during early stage, first episode illness, when symptoms are likely to be more malleable, is seen 
as critical in promoting favourable long-term outcomes. For example, in psychosis, systematic 
reviews and meta-analyses support the association between a shorter duration of untreated 
psychosis (DUP) and better clinical outcomes (Farooq, Large, Nielssen, & Waheed, 2009; 
Marshall et al., 2005; Penttila, Jaaskelainen, Hirvonen, Isohanni, & Miettunen, 2014). 
Analogous arguments support the need for early intervention (EI) in EDs (Currin & Schmidt, 
2005). Firstly, it has long been known that in anorexia nervosa (AN) illness duration is a key 
predictor of outcome (Steinhausen, 2002). Secondly, growing evidence suggests that EDs are 
associated with significant structural and functional brain changes (Seitz, Herpertz-Dahlmann, 
& Konrad, 2016; Van den Eynde et al., 2012). As the typical age of ED onset is during a period, 
when prefrontal brain areas important in self-regulation are developing (Keverne, 2004), this 
has the potential to interfere with normal brain development. Thirdly, it has been recognised 
across different psychiatric disorders that with increasing duration, the illness becomes more 
entrenched and difficult to change. This is proposed to arise from ‘neuroprogression’, i.e. 
neurobiological changes that alter the trajectory of illness (Gama, Kunz, Magalhaes, & 
Kapczinski, 2013; Moylan, Maes, Wray, & Berk, 2013). In EDs, converging neuroimaging and 
cognitive neuroscience data support this idea (Berner & Marsh, 2014; O'Hara, Campbell, & 
Schmidt, 2015; Steinglass & Walsh, 2016). Finally, given the high physical, psychosocial and 
financial burden of EDs, treating  symptoms early is valuable from both an ethical and 
economical perspective (Currin & Schmidt, 2005). 
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Stage-of-illness based ED models incorporate these ideas and findings and suggest that 
stage-appropriate EI may be able to halt illness progression (Currin & Schmidt, 2005; Treasure 
et al., 2015).In England, a Government-led EI initiative, has introduced  specialist ED 
community teams together with waiting time standards for young people below the age of 18 
(NHS, 2015). This initiative is grounded in concerns that across different countries 
hospitalisations of young people with AN are rising (Herpertz-Dahlmann et al., 2014). Studies 
of hospitalisation trends from the 1960s to the present, have shown large recent increases in 
hospitalisation rates in England, with the greatest rise in young women aged 15-19 (Holland, 
Hall, Yeates, & Goldacre, 2016). In contrast, admission rates for most other mental disorders 
have declined (Green & Griffiths, 2014). Pilot data suggest that in areas where specialist EDs 
adolescent outpatient services are available, rates of hospitalisations are significantly lower 
(House et al., 2012).  
However, this initiative only covers part of the UK. Moreover, it does not cover emerging 
adults, who are aged 18 to 25, have a high incidence of AN, and like adolescents, face multiple 
developmental challenges (Arnett, Žukauskienė, & Sugimura, 2014). 
Taken together, there is a strong rationale for EI for EDs but a lack of research. This led us 
to propose an EI service model for emerging adults with early stage EDs (Schmidt et al., 
2016a). Our model is biopsychosocial, with a focus on optimising early care. A pilot evaluation 
of this First Episode Rapid Early Intervention service for ED (FREED) found significantly 
reduced waiting times and duration of untreated ED (Brown et al., 2016). The present study (1) 
assesses ED and other clinical outcomes in FREED patients and their carers, (2) compares 
FREED service utilisation to that of comparable patients seen previously in our service, and 
(3) compares BMI change in FREED anorexia nervosa (AN) patients and comparable AN 
patients seen previously.  
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MATERIALS AND METHODS  
Ethical approval for the project was given on 4th August 2014 by the National Research 
Ethics Service Committee London – South East [ref: 14/LO/0873].  
 
Participants 
FREED cohort: 
Participants were recruited during one year (September 2014 to August 2015) from 
consecutive referrals to the adult ED Outpatient Service at the South London and Maudsley 
NHS Foundation Trust (SLaM), London, UK, a large catchment area based specialist service 
covering a local population of approx. 2 million people. Inclusion criteria were: being aged 18-
25, a primary DSM-5 ED diagnosis and an ED illness duration of ≤ 3 years (This criterion was 
chosen, based on illness staging models of AN, which suggest that after this time illness 
characteristics become more ‘solidified’ and treatment outcomes more muted (Treasure et al., 
2015). Exclusion criteria were: need for immediate inpatient admission that was clear on 
referral (using NICE guidance (2017) to inform decision-making), factors that precluded 
completing questionnaires (severe learning disability, inability to speak English), not being 
available for the 12-month duration of the study, and/or the presence of a primary comorbid 
physical/mental disorder requiring priority treatment (e.g. substance dependence). All other 
comorbid patients were treated within the study. 
Audit cohort  
In order to have a comparison group, we carried out an audit of patients seen in our 
service during the two years prior to implementation of FREED. All patients referred during 
mid May 2012 - mid May 2014 who were aged 18-25 were identified from clinical records. 
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Information regarding ED onset was obtained from clinical assessment letters. Those with an 
illness duration < 3 years were included.  
 
Procedures 
Clinical procedures  
Details of the FREED service model and care pathway are described elsewhere (Brown 
et al., 2016; Schmidt et al., 2016). Briefly, all referrals for individuals aged between 18-25 
years, are screened by telephone (within 48 hours of referral). All telephone screenings were 
carried out by an ED clinician working in the outpatient service with the role of ‘FREED 
champion’. Patients deemed eligible for FREED (and where there are no gate-keeping 
arrangements restricting access to care), are immediately booked in to the next available 
assessment (aiming for < 2 weeks from date referral received). Each screening call took 
approximately 15 minutes to complete. The standard ED assessment protocol used in the 
service was adapted for FREED clinical assessments, i.e. it consists of a biopsychosocial, 
person-centred assessment which considers the young person within their family and social 
context, focusing on their needs, priorities and strengths. Where possible, family members and 
close others join part of the assessment. Attention is paid to the young person’s use of social 
media and health-related apps, given ubiquitous use of these amongst young people and their 
known role in maintaining ED symptoms (Holland & Tiggemann, 2016). Assessing clinicians 
offer psycho-educational information about the effects of the illness on all aspects of the young 
person’s life. A care plan is formulated collaboratively. Individuals eligible for the FREED 
service are rapidly allocated to a therapist (aiming for < 2 weeks from assessment) to start an 
evidence-based, stage-appropriate psychological treatment. For young people with BN and 
BED, treatment is cognitive behavioural therapy (CBT), delivered online, individually or in a 
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group, with typically up to 24 sessions. For young people with AN, individual outpatient 
therapy using the Maudsley Model of Anorexia Nervosa Treatment, a formulation-based 
treatment with a patient workbook, is typically used. Treatment duration typically is 24 to 34 
sessions (Schmidt et al., 2015; Schmidt et al., 2016b). Sessions with family members/carers 
are an integral part of treatment. Pharmacotherapy (e.g. antidepressants) is added as 
appropriate. Early involvement of the team dietician is emphasised to provide an appropriate 
meal plan, particularly for young people with complex nutritional needs. All treating clinicians 
were employees of the South London and Maudsley NHS Foundation Trust. 
Research procedures 
FREED cohort:  
Patients (and where appropriate, their carers) entered into the FREED service were 
invited to participate in the FREED service evaluation study at assessment and were required 
to give their written, informed consent. Following this, patients and, where possible, their 
carers completed the first of four questionnaire packs. This time point is referred to as 
‘baseline’. Participants and carers were asked to complete similar questionnaires packs at 3, 6 
and 12 months following the initial assessment. Patients were followed up irrespective of 
whether they completed treatment.  
Audit cohort: 
For patients in the audit cohort, their referral, assessment and service usage data 
(number of outpatient sessions attended; additional in-patient or day-care treatment during the 
year following assessment) were extracted from their clinical notes. For AN patients, BMI data 
were also extracted from the notes (where possible) within 1 month of each of the four time 
points used in FREED. Questionnaire data were not available for the audit cohort at FREED-
comparable time points. 
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Outcomes  
Process outcomes 
The waiting time for treatment was defined as the time period (in weeks) from the date 
the referral was made (e.g. by the GP) to the date patients attended their first treatment session. 
The waiting time (in weeks) between assessment and treatment was also calculated. Treatment 
uptake was defined as attending a minimum of one treatment session after assessment. Service 
utilisation was also assessed in terms of total number of treatment sessions attended, and the 
need for additional intensive treatment (i.e. day-care or inpatient treatment) during the year 
following assessment.  
Clinical outcomes  
Psychological measures 
Eating Disorder Examination Questionnaire (EDE-Q). Version 6 of the EDE-Q 
(Fairburn & Beglin, 2008) was completed by patients. Questions relate to the past 28 days and 
are measured on a 7-point Likert scale ranging from zero (no days) to six (every day). Four 
subscale-scores (restraint, eating concern, shape concern and weight concern) are calculated 
and based on these a global score. High global scores indicate greater ED psychopathology, 
with a proposed clinical cut-off score of ≥ 2.8 (Mond et al., 2008).  
Clinical Outcomes in Routine Evaluation (CORE-10). A short, 10 item version of 
the CORE-OM was completed by both patients and carers (Barkham et al., 2013). The CORE-
10 is a measure of global distress and functioning. Each item is rated on a 5-point Likert scale 
from ‘not at all’ (0/4) to ‘most or all of the time’ (4/0). The clinical score is calculated by adding 
the values of all 10 items. Scores below 10 are deemed non-clinical, whilst scores of 11 or 
above are within the following clinical ranges: 11-15 mild, 15-20 moderate, 20-25 
moderate/severe and >25 severe.  
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Depression, Anxiety and Stress Scale (DASS-21). The DASS-21, completed by both 
patients and carers, is a short version of a 42 item self-report measure that assesses mood state 
over the past seven days (Lovibond & Lovibond, 1995). It is comprised of 21 items measured 
on a 4-point Likert scale ranging from 0 (did not apply to me at all) to 3 (applied to me very 
much, or most of the time). Each item loads on to one of three subscales, depression, anxiety 
and stress, which when added together provide a total score indicative of general 
psychopathology. A normative baseline cut-off of 13 for the total DASS-21 score has been 
proposed (Crawford & Henry, 2003), and high scores indicate worse symptomatology. 
Work and Social Adjustment Scale (WSAS). The WSAS was completed by both 
patients and carers. It is a 5-item self-report scale designed to measure functional impairment 
attributable to an identified problem, in this case an ED (Marks, 1986). Each item is rated on a 
9-point Likert scale ranging from ‘no impairment’ (0) to ‘very severe impairment’ (8). The 
maximum total score is 40. Scores above 20 suggest moderate-severe psychopathology, scores 
10-20 indicate less severe clinical impairment and scores below 10 are deemed subclinical.  
Clinical Impairment Assessment (CIA). The 22-item CIA was completed by patients. 
It is a self-report measure of the severity of psychosocial impairment due to ED features (Bohn 
et al., 2008). The CIA focuses on the past 28 days and the 22 items cover impairment in 
domains of life typically affected by ED psychopathology, e.g. mood, self-perception, 
cognitive functioning, interpersonal functioning and work performance. Each item is rated on 
a 4-point Likert scale ranging from ‘not at all’ (0) to ‘a lot’ (3). A global CIA impairment score 
is calculated by adding all items together and dividing by the total number of items completed. 
Global CIA scores range from 0 to 3, with a higher score indicative of greater secondary 
psychosocial impairment.  
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Level of Expressed Emotion Scale (LEE). Patient and carer versions of the LEE were 
completed in the current study. The LEE aims to measure the perception of expressed emotion 
in a person’s influential relationships. Both versions of the LEE include 60 items with the 
option of a ‘true’ or ‘false’ response (Cole & Kazarian, 1988). An overall score is generated by 
summing the 38 items, with a higher score indicative of greater perceived expressed emotion.  
Accommodation and Enabling Scale for Eating Disorders (AESED). The AESED 
is a 33-item self-report measure that aims to assess accommodating and enabling behaviours 
of ED carers (Sepulveda, Kyriacou, & Treasure, 2009). Each item is rated on a 5-point Likert 
scale from ‘never/no’ (0) to ‘everyday/extreme’ (4), with the exception of item 24 which is 
transformed into a 5-point Likert scale. A total score is calculated by summing the score on all 
items. A higher score is associated with higher accommodation of ED symptoms.  
Weight and Body Mass Index (BMI) 
Patients’ weight and height was measured and their body mass index (BMI; kg/m2) was 
calculated. These data were taken from clinical notes nearest to the date of the four time points 
(approximately 1 month from the baseline, 3-, 6- and 12-months measurement points) that 
questionnaires were completed. In addition, BMI at the start of treatment was also taken.   
 
Statistical Analyses 
Overall, our analyses followed the recommendations of the Child Outcome Research 
Consortium (CORC) for service data (http://www.corc.uk.net/media/1533/fupsleaflet.pdf). 
The CORC suggestion is to provide accessible descriptive analyses first and foremost, and only 
undertake statistical tests where there is a clear reason to do so. 
With this in mind, statistical analyses followed from the three study aims. Firstly, there 
was a within-group evaluation of the clinical outcomes for the FREED group. To estimate 
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within-group changes in the whole FREED cohort over the course of treatment linear mixed 
models were used. Change was estimated using time as a fixed categorical factor (baseline, 3, 
6 and 12 months) with correlations within patient repeated measures accounted for by inclusion 
of a random intercept for participant and slope to allow change over time to vary by person. 
Changes from baseline to 3, 6 and 12 months and 6 to 12 months were calculated with p values 
and confidence intervals Bonferroni adjusted for multiple comparisons. Using mixed models 
for the analysis fit with maximum likelihood (ML) allows missing data to be included in model 
estimates under the assumption that the data were missing at random. Predictors of missingness 
such as diagnosis, age of onset, treatment completion, gender, ethnicity and BMI at assessment 
were examined. Only diagnosis was found to be a predictor of missingness and was therefore 
included in the mixed model as a covariate.  
Secondly, the relative impact of  FREED on process outcomes was evaluated by 
comparing the FREED cohort with the Audit cohort, constructed from eligible patient notes 
from the period May 2012 –May 2014 inclusive. Between-group demographic and clinical 
baseline features were compared with t-tests, chi-Square tests or Fisher’s exact tests as 
appropriate. Group differences in process outcomes and in particular waiting-times and total 
number of sessions attended were analysed using a generalized linear model with negative 
binomial errors. Proportions were also calculated to compare intensive treatment usage for 
FREED and the Audit group and carer involvement within the FREED group. 
As indicated above, the only clinical information available for the Audit group was 
BMI which was collected from patient records. Thus, in the third and final part of the analysis 
we compared change in BMI for FREED and Audit patients with an AN diagnosis. To do this 
we fitted a linear mixed model with measurement time-point (baseline, 3, 6 and 12 months) 
and group (FREED vs Audit) as main effects and a group by time-point interaction. As for the 
within group analysis, predictors of missing data were sought but none were identified.   
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Statistical analyses were performed using IBM® SPSS® software (Version 23) and Stata 
version 14.1 IC.  
 
 
RESULTS  
Participant flow  
Figure 1 shows the participant flow through the study. Nine ‘FREED pilot cases’ were 
referred before the study period (i.e. prior to September 2014) but treated under the FREED 
service model. These nine cases were not included in the process outcomes we previously 
reported (Brown et al., 2016). However, as they received clinical care within the FREED 
service, we have included them in all outcomes reported here. This left a total of 56 patients in 
the current FREED sample. Nineteen carers (relating to 19 patients) provided longitudinal data. 
In the audit sample (N=86), 22/86 patients only attended an initial assessment and did not take 
up the offer of further treatment within the outpatient service. Therefore the number of audit 
patients with outcomes after initial assessment are N=64. 
 
Baseline characteristics 
Table 1 presents demographic and clinical characteristics for FREED and (audit) 
patients. There were no differences in the FREED and Audit groups in regards to age at referral, 
age of ED onset, sex, or ED diagnoses (p-values between 0.647 and 0.93).  
Clinical outcomes in FREED cohort  
Eating disorder symptoms: 
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Figure 2A shows EDE-Q estimated means for the whole FREED cohort across time. 
Raw data for all patient and carer clinical outcomes are shown in Table 2. In the patient data, 
internal consistency assessed with Cronbach’s alpha at baseline was excellent (i.e. 0.9 < α ) for 
the EDE-Q (α = 0.916), DASS (α = 0.935), LEE (α = 0.95) and CIA (α = 0.936) and good (i.e. 
0.8 < alpha < 0.9) for CORE (α = 0.844) and WASA (α = 0.844). In the carer data, internal 
consistency assessed was excellent (i.e. 0.9 < alpha) for the DASS (α = 0.925), WASA (α = 
0.949) and AESED (α = 0.904), good (i.e. 0.8 < alpha < 0.9) for the CORE (α = 0.809) and 
acceptable (i.e. 0.7 < alpha < 0.9) for the LEE (α = 0.759). Table 3 shows estimated changes 
between baseline and follow-up assessment points. From this it can be seen that all EDE-Q 
follow-up time points differ significantly from baseline (T1) and that significant improvements 
occur between baseline (T1) and 3 months (T2) and 3 months (T2) and 6 months (T3) 
assessments. Between 6 and 12 months assessments a smaller improvement occurs. 
Proportions of patients with an EDE-Q score below the clinical cut-off (i.e. < 2.8; (Mond et al., 
2008) were as follows: T1: 18% (10/56) T2: 33% (13/39), T3: 53% (18/34) and T4:70% 
(19/27).  
 
Other patient and carer outcomes: 
Table 3 also shows estimated changes from baseline for all other patient and carer 
questionnaire outcomes and for patient BMI collected within the whole FREED cohort at 
baseline, 3, 6 and 12 months.  
Patient scores were generally improved from 3, 6 and 12 months compared to the start 
of treatment. Change between 6 and 12 months (when people had mainly finished treatment) 
was generally small showing slight benefit or loss. This indicates improvement of general 
psychopathology, secondary psychosocial impairment and expressed emotion, respectively.  
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Nineteen carers provided questionnaires. Interestingly, carer scores showed strong 
improvements at 12 months but with the majority of the change in scores occurring between 6 
and 12 months. There was improved general psychopathology, expressed emotion and less 
accommodation of ED symptoms in carers of patients in the FREED service.  
 
Process outcomes 
Wait times  
Patients in the FREED cohort waited 19.5 days less than those in the Audit cohort 
from the time their GP made their referral to their initial assessment [FREED median wait 
42.5 days (IQR 23,66) vs Audit cohort 62 days (41,98)],  but this difference was not 
significant (Rate Ratio = 0.74, 95% CI:0.53,1.05; χ2 =2.98; p=0.084). However, the waiting 
time was 14 days shorter from assessment to starting treatment for the FREED cohort versus 
Audit (20 days (IQR 11,31) vs 34 (IQR 16, 125), Rate Ratio = 0.34, 95% CI: 0.23, 0.49) (χ2 
=34.1; p < 0.001).  
 
Treatment usage  
A greater proportion of individuals in FREED, compared to those in the Audit cohort, 
took up treatment after their assessment [FREED: 56 (100%) vs Audit 64/86 (74%); Fisher’s 
exact p < 0.001]. There were no differences between the FREED and Audit cohorts in the 
median number of total sessions attended [FREED: 21.5 (IQR 9,29.5) vs Audit: 16 (IQR 8, 
24); Rate ratio = 1.16, 95% CI: 0.80, 1.70)]. Treatment completion was comparable in both 
groups [FREED 40/56 (71%) and Audit 45/64 (71%)]. The proportions of patients who 
required additional intensive treatment (specialist in-patient care, day-care treatment) for their 
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ED during the 12 months study period were also examined. In the FREED cohort, 8.9% (5/56) 
of patients required additional in-patient or day-care treatment, whereas 14.1% (9/64) of the 
Audit cohort needed such treatment (Fisher’s exact test; p=0.999). 
 
Carer involvement 
Nearly 61% (60.7%; 33/56) of carers had some type of involvement in the treatment. 
This included attending either the assessment, inclusion in some treatment or group sessions. 
 
BMI comparison in FREED AN versus audit AN patients 
Twenty-two FREED patients and 28 Audit patients who entered treatment had an AN 
diagnosis. Figure 2.B shows estimated mean BMI by group (FREED-AN and Audit AN) and 
estimated outcome differences between treatment arms at different time points from start of 
treatment to the follow-up 12 months later. There was no group by time interaction (χ2(3) = 
0.20, p= 0.978). Over time, the marginal BMI was lower in the 28 Audit-AN patients than 
FREED-AN patients, although this difference was not significant (χ2(1) = 2.70, p= 0.100). At 
initial clinical assessment, the mean BMI of the FREED-AN group was 16.4 and Audit-AN 
group was 16.1. (This data point is not included in the figure due to variable waiting times from 
assessment to treatment in the two groups). Between initial assessment and the start of 
treatment, BMI increased for the FREED-AN group to 16.7 but decreased for the Audit-AN 
group to 15.8 (for those entering treatment). This difference of 0.9 BMI-points at the start of 
treatment was maintained across the 6 months (Figure 3).  By 12 months, estimated mean BMI 
in the FREED group had risen further to 18.9, a mean difference of 2.26 (95% CI 1.54, 2.98) 
BMI points compared to the start of treatment. Given missing data it is not clear how 
representative BMI at 12 months in the Audit group is.   
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We also calculated proportions of patients who were weight recovered (defined as BMI 
> 18.5 kg/m2) at each time point. For the FREED cohort these figures were T1: 3/22 (13.6%), 
T2: 2/21 (9.5%); T3: 5/19 (26.3%); T4: 10/17 (58.8%). For the Audit cohort figures were T1: 
1/29 (3.4%), T2: 3/24 (12.5%); T3 3/21 (14.3%); T4: 1/6 (16.7%).  
 
DISCUSSION  
This study investigated the impact of a novel early intervention service on the clinical 
outcomes of patients with ED and their carers, and also examined the impact of the service on 
treatment usage. 
Within the whole transdiagnostic FREED cohort, there were significant and large 
reductions in ED psychopathology over time, as measured by the EDE-Q. Moreover, the 
percentage of individuals with scores below the clinical cut off of the EDE-Q (< 2.8) increased 
from 18% at the start of treatment to 70% at 12 months after starting of treatment. These 
findings are comparable to those found under optimal conditions in recent research cohorts and 
large scale clinical trials, such as the UK-Italy study of CBT-E in AN (Fairburn et al., 2013) 
and the MOSAIC trial (Schmidt et al., 2015; Schmidt et al., 2016b). Similar improvements in 
the FREED cohort were observed across all other clinical outcomes including depression, 
anxiety and stress, CORE-10, work and social adjustment and expressed emotion. In parallel, 
there were improvements on psychological outcomes for FREED carers. Given the significant 
burden and high levels of distress for carers and families (Rhind et al., 2016; Treasure & Nazar, 
2016) these improvements are encouraging. 
Within the FREED AN group, BMI increase over time was excellent and broadly 
comparable to outcomes from a recent large scale clinical trial of family therapy in adolescents 
with AN (Eisler et al., 2016), A high proportion of FREED AN patients (60%) returned to a 
normal BMI (> 18.5kgs/m2) at 12 months. A comparison of BMI change between FREED and 
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Audit patients found non-significant differences in BMI between the groups at several time 
points and a significant difference at 12 months. Of note whilst the BMI of FREED-AN patients 
increased between initial assessment and start of treatment, there was a decrease in the BMI of 
the Audit cohort. This observation is important for two reasons. Firstly, the Audit cohort waited 
significantly longer to start treatment compared with the FREED cohort. The decrease in BMI 
seen in the Audit cohort supports the idea that waiting for treatment is detrimental for patients. 
Secondly, the slight increase in BMI observed in the FREED cohort could be due to the positive 
impact of certain core components of the FREED assessment, such as the motivational and 
engaging style, use of psycho-education and emphasis on illness malleability. These are key 
elements to the FREED model and they are likely to increase patient motivation in this targeted 
age group and led to improved engagement and outcomes. 
In both the FREED and the Audit cohort few patients needed additional intensive 
treatment (FREED 8.9% and Audit 14.06%), i.e. slightly favouring FREED. Against a 
background of national and international trends of rising numbers of hospitalisations in young 
people with AN, this is promising. It is also important as intensive treatments, such as in-patient 
or day-care treatment, are a significant financial burden to health services and far more costly 
than outpatient treatment (Byford et al., 2007; Herpertz-Dahlmann et al., 2014). Reducing the 
likelihood of the need for intensive treatments may also impact on downstream costs, as 
previous inpatient or intensive treatments are a strong predictor of relapse in EDs (Carter, 
Blackmore, Sutandar-Pinnock, & Woodside, 2004). If the FREED service is able to target 
emerging adults in their first illness episode, it may be able to disrupt the course of illness, 
preventing the need for future costly treatment.  
A significant proportion of potentially eligible patients (n=50) could not be included 
into the study for a variety of reasons, such as not being available for treatment due to moving 
away or travelling or simply not responding to our efforts to contact them after referral. This 
18 
 
highlights the transient nature, high mobility, limited treatment motivation and thus 
vulnerability of the emerging adult population for whom the FREED service was designed. 
This suggests that additional alternative avenues for engaging with these young people, e.g. via 
electronic and mobile health tools may be necessary. 
This study has several limitations that should be noted. Firstly, as the audit comparison 
group was collected retrospectively it was only possible to report BMI data as an outcome. 
Secondly, there was a high proportion of missing self-report data at the follow-up stages in the 
FREED cohort. Although this is disappointing, it is still important to report this information. 
The UK Child Outcomes Research Consortium (CORC) acknowledges the difficulties with 
collecting service data, and comment that although such data are often Flawed, Uncertain, 
Proximate and Sparse (FUPS), they should still be shared as this is likely to prompt dialogue 
between key stakeholders and improves care 
(http://www.corc.uk.net/media/1533/fupsleaflet.pdf). 
Furthermore, due to the limited number of participants in the study it was not possible 
to analyse the data for each of the ED diagnoses separately, or in relation to different treatments 
received. We hope that we will be able to provide this information in our future studies. 
 
This study is the first report of clinical outcomes of an early intervention service within 
the ED field. One other study has recently reported on the impact of early intervention in 1st 
episode AN (Gumz, Weigel, Wegscheider, Romer & Löwe., 2017). The intervention comprised 
a comprehensive public health intervention implemented across the Hamburg metropolitan 
area. Patients recruited before and after introduction of the intervention were compared on (a) 
mean duration of untreated illness until specialist treatment and (b) mean duration of illness 
until first contact with the health service. Mean duration of untreated illness was 36.5 months 
before the implementation of the intervention and remained unchanged thereafter (40.1 
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months). Mean duration until first contact with the health service was 25.0 months before 
introduction of the intervention and 32.8 months thereafter, suggesting that help-seeking 
patients face very considerable delays in the German health care system, until they reach 
specialist care. Clinical outcomes are not reported in the German sample.  In this study, baseline 
demographic and clinical features were very similar to those in our sample, but a much higher 
proportion of patients in the German sample (55.9 % pre-intervention and 83.3% post-
intervention) were treated as in-patients (Gumz, et al., 2017).  In our study, duration of 
untreated illness for adult patients was 19.1 months and for FREED patients was 16.4 months. 
Duration of illness till first contact with health services was 16.2 months for audit patients and 
15.7 months for FREED patients (Brown et al., 2016).   
When seen in the context of the German data, our process outcomes and clinical 
outcomes are encouraging and support further evaluation and wider implementation of 
FREED. The scalability of the FREED service is now being evaluated across several specialist 
ED services within the UK National Health Service, with the aim of assessing whether FREED 
is a suitable national model of service delivery.  
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Figure 1. Participant flow diagram 
 
 
 
 
 
 
 
 
 
 
 
 
Patients aged between 18-25yrs assessed during study period (n=201) 
Met inclusion criteria for FREED (age 18-25 & illness duration < 3 years) (n=60) 
Excluded (n=141), with reasons:  
- ED history > 3 years (n=95) 
- Atypical ED/comorbid diagnosis (n=8) 
- Funding not approved (n=3) 
- No further contact (n=29) 
- Other (n=6) 
Patient clinical outcomes (n=56): 
Start treatment (baseline): BMI n=56 (100%); questionnaires n=56 (100%) 
3month assessment: BMI n=46 (82%); questionnaires n=39 (70%) 
6month assessment: BMI n=37 (66%); questionnaires n=35 (62%)  
12month assessment: BMI n=31 (55%); questionnaires n=27 (48%)  
FREED cohort (n=56) 
Excluded (n=4): 
- did not complete baseline 
research assessments (n=4) 
Treatment Uptake and Adherence (n=56): 
Took up treatment: n=56 (100%; in-patient n =1, outpatient n=55) 
Average total number of individual treatment sessions attended: 21.02 
Dropped out (i.e. discontinued treatment against clinical advice/disengaged): n=13 
Didn’t complete treatment as moved out of catchment area: n=5 
Completed n=38  
 
FREED 
Audit cohort (n=86) 
Treatment Uptake and Adherence (n=86): 
Took up treatment: n=64 (74%; in-patient n=4, outpatient n=60) 
Average total number of individual treatment sessions attended: 17.61 
Dropped out (i.e. discontinued treatment against clinical advice/disengaged): n=18 
Completed n=46, total n=46 
Patient clinical outcomes analysis (n=64): 
Start treatment: BMI n=49 (76%)  
3month assessment: BMI n=41 (76%)  
6month assessment: BMI n=36 (56%)  
12month assessment: BMI n=8 (12%)  
Patients aged between 18-25yrs seen 2 years prior to FREED (n=301) 
Audit 
Excluded (n=215), with reasons:  
- ED history > 3 years (n=76) 
- Unable to ascertain onset (n=130)  
- Did not have an ED diagnosis (n=2) 
- No further contact (n=7) 
Met FREED matched inclusion criteria (age 18-25 & illness duration < 3 years) (n=86) 
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Figures 2A and 2B. Estimated means (and 95% CI) for (A) EDE-Q for all FREED patients (n=53) and (B) BMI from start of treatment 
(T 0 months) to 12 months assessment for FREED (n=22, n=17) versus Audit (n=28, n=6) anorexia nervosa patients. 
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TABLES 
Table 1. Demographic and clinical baseline characteristics. 
 
FREED cohort 
(N=56) 
Audit cohort (N=86) 
Age on  GP referral (years): mean 
(SD) 
20.4 (2.4) 20.4 (2.0) 
Gender (Female): n (%) 54 (96%) 85 (98%) 
Clinical Baseline   
Age of onset (years): mean (SD) 
19.3 (2.6) 19.3 (2.1) 
Diagnosis 
 
  
AN: n (%) 22 (35%) 35 (40%) 
BN: n (%) 18 (32%) 24 (28%) 
BED: n (%) 1 (2%) 4 (5%) 
OSFED: n (%) 15 (27%) 23 (27%) 
 
AN = anorexia nervosa; BN = bulimia nervosa; BED = binge eating disorder; OSFED = other specified feeding or eating disorder  
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Table 2. Raw data of psychological outcomes in FREED cohort: patients and carers  
 
Baseline  
3 
months 
 
6 
months 
 
12 
months 
 
 n  Score  n  Score n Score n Score 
PATIENTS         
Eating Disorders 
Examination (EDE) 
53 
4.0 
(1.3) 
37 
3.2 
(1.4) 
32 
2.5 
(1.4) 
25 
2.2 
(1.6) 
Body Mass Index 
(BMI) 
50 
19.8 
(3.7) 
45 
19.7 
(3.3) 
35 
19.9 
(2.9) 
30 
20.7 
(3.2) 
Clinical Outcomes in 
Routine Evaluation 
(CORE-10) 
53 
19.8 
(8.2) 
37 
16.1 
(7.0) 
32 
14.2 
(7.8) 
25 
15.4 
(8.3) 
Depression Anxiety and 
Stress Scale (DASS) 
51 
32.7 
(13.7) 
37 
24.3 
(15.5) 
33 
21.1 
(14.6) 
26 
23.0 
(14.0) 
Work and Social 
Adjustment Scale 
(WSAS) 
51 
21.0 
(9.7) 
36 
18.1 
(9.7) 
32 
14.5 
(10.5) 
26 
11.8 
(10.3) 
Levels of Expressed 
Emotion Scale (LEE) 
51 
17.3 
(11.0) 
37 
14.9 
(9.9) 
31 
12.0 
(7.4) 
26 
12.2 
(12.3) 
Clinical Impairment 
Assessment (CIA) 
52 
1.8 
(0.62) 
32 
1.67 
(0.66) 
33 
1.20 
(0.69) 
26 
1.0 
(0.71) 
         
CARERS         
Clinical Outcomes in 
Routine Evaluation 
(CORE-10) 
16 
10.4 
(5.9)  
17 
9.6 
(7.2)  
14 
10.0 
(4.5) 
13 
4.9 
(3.5) 
Depression Anxiety and 
Stress Scale (DASS)  
16 
10.3 
(8.9)  
17 
10.1 
(9.2) 
13 
10.6 
(8.7) 
13 
3.1 
(4.3) 
32 
 
Work and Social 
Adjustment Scale 
(WSAS)  
16 
8.9 
(10.0) 
17 
10.1 
(8.3) 
14 
9.4 
(9.3) 
14 
4.1  
(4.3) 
Levels of Expressed 
Emotion Scale (LEE) 
18 
8.7 
(4.6) 
18 
8.6 
(6.3) 
14 
8.8 
(5.1) 
14 
6.4 
(4.3) 
Accomodation and 
Enabling Scale 
(AESED) 
15 
37.7 
(18.2) 
18 
35.7 
(19.6) 
11 
35.3 
(22.0) 
13 
22.2 
(11.2) 
 
Cut-off scores: 10 item Clinical Outcomes in Routine Evaluation (CORE-10): scores of 11-15 mild, 15-20 moderate, 20-25 moderate/severe and 
>25 severe; 21 item Depression, Anxiety and Stress Scale (DASS-21): total score of 13 is normative baseline; Work and Social Adjustment Scale 
(WSAS): >20 moderate-severe, 10-20 moderate, <10 subclinical; higher scores on the Level of Expressed Emotion (LEE) indicative of greater 
perceived expressed emotion (no severity score ranges available). higher scores on the Clinical Impairment Assessment (CIA) indicative of worse 
secondary psychosocial impairment (no severity score ranges available); and higher scores on the Accommodation and Enabling Scale for Eating 
Disorders (AESED) indicative of higher accommodation to ED symptoms (no severity score ranges available).  
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Table 3:  Estimated mean change on clinical outcomes from baseline for patients and carers at 3, 6 and 12 months and from 6 to 12 months, with 
standardised regression coefficients. and p-values and 95% CI Bonferroni adjusted for multiple comparisons (4 comparisons per outcome). SES 
(standardised effect size) here are regression coefficients standardised by dividing by the baseline standard deviation (Hedges & Olkin, 1985).  
 
 0 - 3 months 
 
0 - 6 months 0 - 12 months 6 – 12 months 
 β, 
95%CI 
z 
p 
SES β, 
95%CI 
z 
p 
SES β, 
95%CI 
z 
p 
SES β, 
95%CI 
z 
p 
SES 
Patients 
 
            
Eating 
Disorders 
Examination 
(EDE) 
-0.82 
-1.21, -0.43 
-5.27 
0.001 
-0.63 -1.55 
-2.06, -1.05 
-7.70 
0.001 
-1.19 -2.08 
-2.76, -1.41 
-7.76 
0.001 
-1.60 -0.53 
-1.02, -0.03 
-2.67 
0.030 
-0.28 
BMI  0.16 
-0.40, 0.71 
0.71 
1.00 
0.04 0.69 
-0.02, 1.41 
2.41 
0.064 
0.19 1.20 
0.29, 2.12 
3.28 
0.004 
0.9 0.51 
-0.16, 1.18 
1.90 
0.229 
0.14 
Clinical 
Outcomes in 
Routine 
Evaluation 
(CORE-10) 
-3.61 
-6.81, -0.42 
-2.82 
0.019 
-0.44 -5.57 
-9.00, -2.13 
-4.05 
0.001 
-0.68 -5.43 
-9.33, -1.54 
-3.48 
0.002 
-0.66 0.13 
-3.83, 4.09 
0.08 
1.00 
0.02 
Depression 
Anxiety and 
Stress Scale 
(DASS) 
-9.09 
-14.94, -3.25 
-3.89 
0.001 
-0.66 -12.21 
-18.24, -6.17 
-5.05 
0.001 
-0.89 -12.33 
-18.92 -5.74 
-4.67 
0.001 
-0.90 -0.12 
-5.49, 5.27 
-0.04 
1.00 
-0.01 
Work and 
Social 
Adjustment 
Scale (WSAS)  
-2.87 
-7.07, 1.34 
-1.70 
0.354 
-0.30 -7.16 
-11.74, -2.58 
-3.91 
0.001 
-0.74 -10.21 
-15.50, -2.58 
-4.81 
0.001 
-1.05 -3.04 
-8.13, 2.05 
-1.49 
0.541 
-0.31 
Levels of 
Expressed 
-1.45 
-4.96, 2.06 
-1.03 
1.00 
-0.13 -3.52 
-7.35, 0.32 
-2.29 
0.088 
-0.32 -3.86 
-8.17, 0.46 
-2.23 
0.102 
-0.35 -0.34 
-4.66, 3.98 
-0.20 
1.00 
-0.03 
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Emotion Scale 
(LEE) 
Clinical 
Impairment 
Assessment 
(CIA) 
-0.18 
-0.47, 0.10 
-1.64 
0.102 
-0.29 -0.66 
-0.95, -0.36 
-5.52 
0.001 
-1.06 -0.98 
-1.33, -0.63 
-7.03 
0.001 
-1.58 -0.33 
-0.66, 0.00 
-2.48 
0.053 
-0.53 
Carers 
 
            
Clinical 
Outcomes in 
Routine 
Evaluation 
(CORE-10) 
-1.39 
-5.07, 2.29 
-0.94 
1.00 
-0.24 -1.67 
-5.56, 2.22 
-1.07 
1.00 
-0.28 -6.92 
-10.91, -2.93 
-4.33 
0.001 
-1.17 -5.25 
-9.14, -1.36 
-3.37 
0.003 
-0.89 
Depression 
Anxiety and 
Stress Scale 
(DASS)  
-0.51 
-6.44, 5.43 
-0.21 
1.00 
-0.06 -0.26 
-6.74, 6.22 
-0.10 
1.00 
-0.03 -7.28 
-13.70, -0.86 
-2.83 
0.019 
-0.82 -7.02 
-13.41, -0.63 
-2.74 
0.024 
-0.79 
Work and 
Social 
Adjustment 
Scale (WSAS)  
-0.94 
-6.98, 5.11 
-0.39 
1.00 
-0.09 -2.99 
-9.43, 3.45 
-1.16 
0.984 
-0.30 -8.16 
-14.54, -1.78 
-3.20 
0.006 
-0.82 -5.17 
-11.30, 0.96 
-2.11 
0.141 
-0.52 
Levels of 
Expressed 
Emotion Scale 
(LEE)  
-0.39 
-3.06, 3.83 
0.28 
1.00 
-0.08 0.09 
-3.62, 3.80 
0.06 
1.00 
0.02 -2.25 
-5.93, 1.42 
-1.59 
0.503 
-0.49 -2.35 
-6.09, 1.39 
-1.57 
0.468 
-0.51 
Accomodation 
and Enabling 
Scale (AESED) 
-3.63 
-14.58, 7.33 
-0.83 
1.00 
-0.20 -5.75 
-18.46, 6.96 
-1.13 
1.00 
-0.32 -18.5 
-30.5, -6.56 
-3.87 
0.001 
-1.02 -12.78 
-24.84, -0.72 
-2.65 
0.032 
-0.70 
  
 
 
